Grail Stock Surges After Favorable FDA Panel Vote on Galleri Cancer Test

Shares of Grail Inc. (GRAL) surged more than 11% in pre-market trading Tuesday after a key advisory panel to the U.S. Food and Drug Administration (FDA) backed the company's multi-cancer early detection blood test, a pivotal development in its path toward commercial approval.

Panel Delivers Favorable Verdict

The FDA’s Molecular and Clinical Genetics Panel voted 7-2, with one abstention, that the benefits of Grail's Galleri test outweigh its risks for adults aged 50 and older. The panel's recommendation followed a review of the test, which is designed to detect more than 50 types of cancer from a single blood draw.

The committee also voted unanimously, 10-0, in support of the test's safety. A vote on Galleri's effectiveness was narrower at 6-4, with some panelists noting that the test should be used to supplement, not replace, existing cancer screening guidelines.

Market Reaction and Analyst Upgrades

Investors reacted positively to the news, sending Grail's stock up 11.3% to $120.81 in pre-open trading, as reported by Investing.com. The move is the latest phase of a rally that began on September 21, when FDA staff released briefing documents that did not raise major concerns about the test's safety or accuracy.

Wall Street analysts responded swiftly to the panel's decision:

Ad

• Baird raised its price target on Grail to $118 from $86 and maintained its Outperform rating.
• Canaccord Genuity reiterated its Buy rating on the stock.
• Mizuho noted that the FDA's earlier documents were supportive of an approval pathway.

The stock's sharp advance came in defiance of a broader market downturn, underscoring the company-specific nature of the catalyst.

Path to Full Approval

While the advisory committee's vote is a significant milestone, it is a non-binding recommendation. The FDA will make the final decision on Grail's Premarket Approval (PMA) application in the coming months.

Investors and the company now await the agency's final verdict. Key uncertainties remain around the test's final labeling, potential requirements for post-approval studies, and the scope of coverage by insurers, all of which will be critical for Galleri's commercial trajectory.